nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—Folic Acid Metabolism Inhibitors—Methotrexate—urinary bladder cancer	0.324	1	CiPCiCtD
Pemetrexed—Methotrexate—urinary bladder cancer	0.21	1	CrCtD
Pemetrexed—TYMS—urinary bladder cancer	0.105	1	CbGaD
Pemetrexed—Pralatrexate—Methotrexate—urinary bladder cancer	0.0278	0.2	CrCrCtD
Pemetrexed—Raltitrexed—Methotrexate—urinary bladder cancer	0.0278	0.2	CrCrCtD
Pemetrexed—Tetrahydrofolic acid—Methotrexate—urinary bladder cancer	0.0278	0.2	CrCrCtD
Pemetrexed—Folic Acid—Methotrexate—urinary bladder cancer	0.0278	0.2	CrCrCtD
Pemetrexed—Leucovorin—Methotrexate—urinary bladder cancer	0.0278	0.2	CrCrCtD
Pemetrexed—ATIC—Methotrexate—urinary bladder cancer	0.0244	0.159	CbGbCtD
Pemetrexed—SLC29A1—Gemcitabine—urinary bladder cancer	0.0198	0.128	CbGbCtD
Pemetrexed—SLC46A1—Methotrexate—urinary bladder cancer	0.0194	0.126	CbGbCtD
Pemetrexed—TYMS—Gemcitabine—urinary bladder cancer	0.0183	0.119	CbGbCtD
Pemetrexed—DCK—Gemcitabine—urinary bladder cancer	0.0183	0.119	CbGbCtD
Pemetrexed—SLC29A1—Fluorouracil—urinary bladder cancer	0.0169	0.11	CbGbCtD
Pemetrexed—TYMS—Fluorouracil—urinary bladder cancer	0.0157	0.102	CbGbCtD
Pemetrexed—DHFR—Methotrexate—urinary bladder cancer	0.0124	0.0806	CbGbCtD
Pemetrexed—TYMS—Methotrexate—urinary bladder cancer	0.00864	0.0562	CbGbCtD
Pemetrexed—GART—prostate gland—urinary bladder cancer	0.000905	0.0642	CbGeAlD
Pemetrexed—GART—seminal vesicle—urinary bladder cancer	0.000766	0.0543	CbGeAlD
Pemetrexed—SLC46A1—prostate gland—urinary bladder cancer	0.000735	0.0521	CbGeAlD
Pemetrexed—SLC46A1—seminal vesicle—urinary bladder cancer	0.000622	0.0441	CbGeAlD
Pemetrexed—GART—renal system—urinary bladder cancer	0.000617	0.0438	CbGeAlD
Pemetrexed—ATIC—prostate gland—urinary bladder cancer	0.000615	0.0436	CbGeAlD
Pemetrexed—GART—urethra—urinary bladder cancer	0.000606	0.043	CbGeAlD
Pemetrexed—Pralatrexate—SLC19A1—urinary bladder cancer	0.000499	0.341	CrCbGaD
Pemetrexed—GART—female reproductive system—urinary bladder cancer	0.000494	0.0351	CbGeAlD
Pemetrexed—ATIC—epithelium—urinary bladder cancer	0.000452	0.032	CbGeAlD
Pemetrexed—GART—vagina—urinary bladder cancer	0.000447	0.0317	CbGeAlD
Pemetrexed—ATIC—smooth muscle tissue—urinary bladder cancer	0.000435	0.0309	CbGeAlD
Pemetrexed—ATIC—renal system—urinary bladder cancer	0.000419	0.0297	CbGeAlD
Pemetrexed—TYMS—prostate gland—urinary bladder cancer	0.000417	0.0296	CbGeAlD
Pemetrexed—DHFR—prostate gland—urinary bladder cancer	0.000413	0.0293	CbGeAlD
Pemetrexed—SLC29A1—prostate gland—urinary bladder cancer	0.000374	0.0265	CbGeAlD
Pemetrexed—DCK—prostate gland—urinary bladder cancer	0.000357	0.0253	CbGeAlD
Pemetrexed—DHFR—seminal vesicle—urinary bladder cancer	0.000349	0.0248	CbGeAlD
Pemetrexed—ATIC—female reproductive system—urinary bladder cancer	0.000336	0.0238	CbGeAlD
Pemetrexed—DCK—seminal vesicle—urinary bladder cancer	0.000302	0.0214	CbGeAlD
Pemetrexed—TYMS—smooth muscle tissue—urinary bladder cancer	0.000295	0.0209	CbGeAlD
Pemetrexed—GART—lymph node—urinary bladder cancer	0.000289	0.0205	CbGeAlD
Pemetrexed—DHFR—renal system—urinary bladder cancer	0.000281	0.02	CbGeAlD
Pemetrexed—DHFR—urethra—urinary bladder cancer	0.000276	0.0196	CbGeAlD
Pemetrexed—SLC29A1—renal system—urinary bladder cancer	0.000255	0.0181	CbGeAlD
Pemetrexed—SLC29A1—urethra—urinary bladder cancer	0.00025	0.0178	CbGeAlD
Pemetrexed—DCK—urethra—urinary bladder cancer	0.000239	0.017	CbGeAlD
Pemetrexed—SLC46A1—lymph node—urinary bladder cancer	0.000235	0.0166	CbGeAlD
Pemetrexed—TYMS—female reproductive system—urinary bladder cancer	0.000228	0.0161	CbGeAlD
Pemetrexed—DHFR—female reproductive system—urinary bladder cancer	0.000225	0.016	CbGeAlD
Pemetrexed—Methotrexate—SLC19A1—urinary bladder cancer	0.00022	0.15	CrCbGaD
Pemetrexed—TYMS—vagina—urinary bladder cancer	0.000206	0.0146	CbGeAlD
Pemetrexed—SLC29A1—female reproductive system—urinary bladder cancer	0.000204	0.0145	CbGeAlD
Pemetrexed—DHFR—vagina—urinary bladder cancer	0.000204	0.0145	CbGeAlD
Pemetrexed—DCK—Doxorubicin—Valrubicin—urinary bladder cancer	0.000198	0.296	CbGdCrCtD
Pemetrexed—DCK—Epirubicin—Valrubicin—urinary bladder cancer	0.000198	0.296	CbGdCrCtD
Pemetrexed—ATIC—lymph node—urinary bladder cancer	0.000196	0.0139	CbGeAlD
Pemetrexed—DCK—female reproductive system—urinary bladder cancer	0.000195	0.0138	CbGeAlD
Pemetrexed—Raltitrexed—TYMS—urinary bladder cancer	0.000191	0.131	CrCbGaD
Pemetrexed—SLC29A1—vagina—urinary bladder cancer	0.000185	0.0131	CbGeAlD
Pemetrexed—DCK—vagina—urinary bladder cancer	0.000176	0.0125	CbGeAlD
Pemetrexed—Pralatrexate—TYMS—urinary bladder cancer	0.000145	0.099	CrCbGaD
Pemetrexed—Leucovorin—TYMS—urinary bladder cancer	0.000145	0.099	CrCbGaD
Pemetrexed—TYMS—lymph node—urinary bladder cancer	0.000133	0.00944	CbGeAlD
Pemetrexed—DHFR—lymph node—urinary bladder cancer	0.000132	0.00935	CbGeAlD
Pemetrexed—SLC29A1—lymph node—urinary bladder cancer	0.000119	0.00847	CbGeAlD
Pemetrexed—DCK—lymph node—urinary bladder cancer	0.000114	0.00809	CbGeAlD
Pemetrexed—TYMS—Podofilox—Etoposide—urinary bladder cancer	9.95e-05	0.149	CbGdCrCtD
Pemetrexed—Folic Acid—MTHFR—urinary bladder cancer	7.42e-05	0.0508	CrCbGaD
Pemetrexed—Tetrahydrofolic acid—MTHFR—urinary bladder cancer	7.42e-05	0.0508	CrCbGaD
Pemetrexed—DCK—Doxorubicin—Epirubicin—urinary bladder cancer	6.9e-05	0.103	CbGdCrCtD
Pemetrexed—Methotrexate—TYMS—urinary bladder cancer	6.39e-05	0.0437	CrCbGaD
Pemetrexed—DCK—Epirubicin—Doxorubicin—urinary bladder cancer	6.38e-05	0.0954	CbGdCrCtD
Pemetrexed—Methotrexate—MTHFR—urinary bladder cancer	5.08e-05	0.0347	CrCbGaD
Pemetrexed—TYMS—Azacitidine—Gemcitabine—urinary bladder cancer	4.01e-05	0.06	CbGdCrCtD
Pemetrexed—Decreased appetite—Fluorouracil—urinary bladder cancer	2.73e-05	0.00109	CcSEcCtD
Pemetrexed—Pancytopenia—Methotrexate—urinary bladder cancer	2.73e-05	0.00109	CcSEcCtD
Pemetrexed—Anaphylactic shock—Etoposide—urinary bladder cancer	2.73e-05	0.00109	CcSEcCtD
Pemetrexed—Mood swings—Doxorubicin—urinary bladder cancer	2.73e-05	0.00109	CcSEcCtD
Pemetrexed—Asthenia—Thiotepa—urinary bladder cancer	2.72e-05	0.00109	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	2.71e-05	0.00109	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	2.71e-05	0.00109	CcSEcCtD
Pemetrexed—Infection—Etoposide—urinary bladder cancer	2.71e-05	0.00109	CcSEcCtD
Pemetrexed—Blood creatinine increased—Doxorubicin—urinary bladder cancer	2.7e-05	0.00108	CcSEcCtD
Pemetrexed—Dysphagia—Epirubicin—urinary bladder cancer	2.69e-05	0.00108	CcSEcCtD
Pemetrexed—Neutropenia—Methotrexate—urinary bladder cancer	2.69e-05	0.00108	CcSEcCtD
Pemetrexed—Pruritus—Thiotepa—urinary bladder cancer	2.69e-05	0.00108	CcSEcCtD
Pemetrexed—Pain—Fluorouracil—urinary bladder cancer	2.69e-05	0.00108	CcSEcCtD
Pemetrexed—Dehydration—Doxorubicin—urinary bladder cancer	2.68e-05	0.00107	CcSEcCtD
Pemetrexed—Thrombocytopenia—Etoposide—urinary bladder cancer	2.67e-05	0.00107	CcSEcCtD
Pemetrexed—Dyspnoea—Cisplatin—urinary bladder cancer	2.65e-05	0.00106	CcSEcCtD
Pemetrexed—Skin disorder—Etoposide—urinary bladder cancer	2.65e-05	0.00106	CcSEcCtD
Pemetrexed—Pancreatitis—Epirubicin—urinary bladder cancer	2.64e-05	0.00106	CcSEcCtD
Pemetrexed—Angina pectoris—Epirubicin—urinary bladder cancer	2.62e-05	0.00105	CcSEcCtD
Pemetrexed—Anorexia—Etoposide—urinary bladder cancer	2.6e-05	0.00104	CcSEcCtD
Pemetrexed—Diarrhoea—Thiotepa—urinary bladder cancer	2.6e-05	0.00104	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	2.59e-05	0.00104	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	2.59e-05	0.00104	CcSEcCtD
Pemetrexed—Decreased appetite—Cisplatin—urinary bladder cancer	2.59e-05	0.00104	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	2.57e-05	0.00103	CcSEcCtD
Pemetrexed—Infestation NOS—Methotrexate—urinary bladder cancer	2.56e-05	0.00103	CcSEcCtD
Pemetrexed—Infestation—Methotrexate—urinary bladder cancer	2.56e-05	0.00103	CcSEcCtD
Pemetrexed—Pancytopenia—Epirubicin—urinary bladder cancer	2.55e-05	0.00102	CcSEcCtD
Pemetrexed—Pain—Cisplatin—urinary bladder cancer	2.55e-05	0.00102	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	2.54e-05	0.00102	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	2.54e-05	0.00102	CcSEcCtD
Pemetrexed—Body temperature increased—Gemcitabine—urinary bladder cancer	2.53e-05	0.00101	CcSEcCtD
Pemetrexed—Renal failure—Methotrexate—urinary bladder cancer	2.52e-05	0.00101	CcSEcCtD
Pemetrexed—Neutropenia—Epirubicin—urinary bladder cancer	2.51e-05	0.00101	CcSEcCtD
Pemetrexed—Dizziness—Thiotepa—urinary bladder cancer	2.51e-05	0.00101	CcSEcCtD
Pemetrexed—Stomatitis—Methotrexate—urinary bladder cancer	2.5e-05	0.001	CcSEcCtD
Pemetrexed—Urticaria—Fluorouracil—urinary bladder cancer	2.5e-05	0.001	CcSEcCtD
Pemetrexed—Conjunctivitis—Methotrexate—urinary bladder cancer	2.49e-05	0.000998	CcSEcCtD
Pemetrexed—Dysphagia—Doxorubicin—urinary bladder cancer	2.49e-05	0.000997	CcSEcCtD
Pemetrexed—Body temperature increased—Fluorouracil—urinary bladder cancer	2.48e-05	0.000995	CcSEcCtD
Pemetrexed—Pancreatitis—Doxorubicin—urinary bladder cancer	2.44e-05	0.000978	CcSEcCtD
Pemetrexed—Dyspnoea—Etoposide—urinary bladder cancer	2.43e-05	0.000975	CcSEcCtD
Pemetrexed—Angina pectoris—Doxorubicin—urinary bladder cancer	2.42e-05	0.000971	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Methotrexate—urinary bladder cancer	2.42e-05	0.000971	CcSEcCtD
Pemetrexed—Vomiting—Thiotepa—urinary bladder cancer	2.41e-05	0.000968	CcSEcCtD
Pemetrexed—Infestation—Epirubicin—urinary bladder cancer	2.4e-05	0.000961	CcSEcCtD
Pemetrexed—Infestation NOS—Epirubicin—urinary bladder cancer	2.4e-05	0.000961	CcSEcCtD
Pemetrexed—Rash—Thiotepa—urinary bladder cancer	2.39e-05	0.00096	CcSEcCtD
Pemetrexed—Dermatitis—Thiotepa—urinary bladder cancer	2.39e-05	0.000959	CcSEcCtD
Pemetrexed—Agranulocytosis—Methotrexate—urinary bladder cancer	2.39e-05	0.000958	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	2.38e-05	0.000953	CcSEcCtD
Pemetrexed—Decreased appetite—Etoposide—urinary bladder cancer	2.37e-05	0.00095	CcSEcCtD
Pemetrexed—Pancytopenia—Doxorubicin—urinary bladder cancer	2.36e-05	0.000947	CcSEcCtD
Pemetrexed—Renal failure—Epirubicin—urinary bladder cancer	2.36e-05	0.000944	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Etoposide—urinary bladder cancer	2.35e-05	0.000944	CcSEcCtD
Pemetrexed—Body temperature increased—Cisplatin—urinary bladder cancer	2.35e-05	0.000943	CcSEcCtD
Pemetrexed—Fatigue—Etoposide—urinary bladder cancer	2.35e-05	0.000942	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Epirubicin—urinary bladder cancer	2.35e-05	0.000942	CcSEcCtD
Pemetrexed—Stomatitis—Epirubicin—urinary bladder cancer	2.34e-05	0.000937	CcSEcCtD
Pemetrexed—Constipation—Etoposide—urinary bladder cancer	2.33e-05	0.000935	CcSEcCtD
Pemetrexed—Pain—Etoposide—urinary bladder cancer	2.33e-05	0.000935	CcSEcCtD
Pemetrexed—Conjunctivitis—Epirubicin—urinary bladder cancer	2.33e-05	0.000934	CcSEcCtD
Pemetrexed—Neutropenia—Doxorubicin—urinary bladder cancer	2.33e-05	0.000932	CcSEcCtD
Pemetrexed—Hypersensitivity—Fluorouracil—urinary bladder cancer	2.31e-05	0.000927	CcSEcCtD
Pemetrexed—Hepatitis—Methotrexate—urinary bladder cancer	2.3e-05	0.000922	CcSEcCtD
Pemetrexed—Asthenia—Gemcitabine—urinary bladder cancer	2.29e-05	0.000919	CcSEcCtD
Pemetrexed—Pharyngitis—Methotrexate—urinary bladder cancer	2.28e-05	0.000915	CcSEcCtD
Pemetrexed—Urinary tract disorder—Methotrexate—urinary bladder cancer	2.27e-05	0.00091	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Epirubicin—urinary bladder cancer	2.27e-05	0.000909	CcSEcCtD
Pemetrexed—Pruritus—Gemcitabine—urinary bladder cancer	2.26e-05	0.000906	CcSEcCtD
Pemetrexed—Nausea—Thiotepa—urinary bladder cancer	2.26e-05	0.000904	CcSEcCtD
Pemetrexed—Urethral disorder—Methotrexate—urinary bladder cancer	2.25e-05	0.000903	CcSEcCtD
Pemetrexed—Agranulocytosis—Epirubicin—urinary bladder cancer	2.24e-05	0.000897	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Etoposide—urinary bladder cancer	2.23e-05	0.000894	CcSEcCtD
Pemetrexed—Pruritus—Fluorouracil—urinary bladder cancer	2.22e-05	0.000891	CcSEcCtD
Pemetrexed—Infestation NOS—Doxorubicin—urinary bladder cancer	2.22e-05	0.000889	CcSEcCtD
Pemetrexed—Infestation—Doxorubicin—urinary bladder cancer	2.22e-05	0.000889	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	2.2e-05	0.000881	CcSEcCtD
Pemetrexed—Hypersensitivity—Cisplatin—urinary bladder cancer	2.19e-05	0.000879	CcSEcCtD
Pemetrexed—Diarrhoea—Gemcitabine—urinary bladder cancer	2.19e-05	0.000876	CcSEcCtD
Pemetrexed—Renal failure—Doxorubicin—urinary bladder cancer	2.18e-05	0.000874	CcSEcCtD
Pemetrexed—Erythema multiforme—Methotrexate—urinary bladder cancer	2.17e-05	0.000871	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	2.17e-05	0.000871	CcSEcCtD
Pemetrexed—Urticaria—Etoposide—urinary bladder cancer	2.17e-05	0.000868	CcSEcCtD
Pemetrexed—Stomatitis—Doxorubicin—urinary bladder cancer	2.16e-05	0.000867	CcSEcCtD
Pemetrexed—Abdominal pain—Etoposide—urinary bladder cancer	2.16e-05	0.000864	CcSEcCtD
Pemetrexed—Body temperature increased—Etoposide—urinary bladder cancer	2.16e-05	0.000864	CcSEcCtD
Pemetrexed—Conjunctivitis—Doxorubicin—urinary bladder cancer	2.16e-05	0.000864	CcSEcCtD
Pemetrexed—Hepatitis—Epirubicin—urinary bladder cancer	2.15e-05	0.000863	CcSEcCtD
Pemetrexed—Eye disorder—Methotrexate—urinary bladder cancer	2.15e-05	0.000861	CcSEcCtD
Pemetrexed—Diarrhoea—Fluorouracil—urinary bladder cancer	2.15e-05	0.000861	CcSEcCtD
Pemetrexed—Asthenia—Cisplatin—urinary bladder cancer	2.14e-05	0.000856	CcSEcCtD
Pemetrexed—Pharyngitis—Epirubicin—urinary bladder cancer	2.14e-05	0.000856	CcSEcCtD
Pemetrexed—Urinary tract disorder—Epirubicin—urinary bladder cancer	2.13e-05	0.000852	CcSEcCtD
Pemetrexed—Urethral disorder—Epirubicin—urinary bladder cancer	2.11e-05	0.000845	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	2.1e-05	0.000841	CcSEcCtD
Pemetrexed—Dizziness—Fluorouracil—urinary bladder cancer	2.08e-05	0.000832	CcSEcCtD
Pemetrexed—Agranulocytosis—Doxorubicin—urinary bladder cancer	2.07e-05	0.00083	CcSEcCtD
Pemetrexed—Diarrhoea—Cisplatin—urinary bladder cancer	2.04e-05	0.000816	CcSEcCtD
Pemetrexed—Erythema multiforme—Epirubicin—urinary bladder cancer	2.03e-05	0.000816	CcSEcCtD
Pemetrexed—Alopecia—Methotrexate—urinary bladder cancer	2.03e-05	0.000814	CcSEcCtD
Pemetrexed—Vomiting—Gemcitabine—urinary bladder cancer	2.03e-05	0.000814	CcSEcCtD
Pemetrexed—Rash—Gemcitabine—urinary bladder cancer	2.01e-05	0.000807	CcSEcCtD
Pemetrexed—Dermatitis—Gemcitabine—urinary bladder cancer	2.01e-05	0.000806	CcSEcCtD
Pemetrexed—Eye disorder—Epirubicin—urinary bladder cancer	2.01e-05	0.000806	CcSEcCtD
Pemetrexed—Hypersensitivity—Etoposide—urinary bladder cancer	2.01e-05	0.000805	CcSEcCtD
Pemetrexed—Erythema—Methotrexate—urinary bladder cancer	2e-05	0.000802	CcSEcCtD
Pemetrexed—Malnutrition—Methotrexate—urinary bladder cancer	2e-05	0.000802	CcSEcCtD
Pemetrexed—Vomiting—Fluorouracil—urinary bladder cancer	2e-05	0.0008	CcSEcCtD
Pemetrexed—Hepatitis—Doxorubicin—urinary bladder cancer	1.99e-05	0.000798	CcSEcCtD
Pemetrexed—Rash—Fluorouracil—urinary bladder cancer	1.98e-05	0.000794	CcSEcCtD
Pemetrexed—Dermatitis—Fluorouracil—urinary bladder cancer	1.98e-05	0.000793	CcSEcCtD
Pemetrexed—Pharyngitis—Doxorubicin—urinary bladder cancer	1.98e-05	0.000792	CcSEcCtD
Pemetrexed—Urinary tract disorder—Doxorubicin—urinary bladder cancer	1.97e-05	0.000788	CcSEcCtD
Pemetrexed—Dysgeusia—Methotrexate—urinary bladder cancer	1.96e-05	0.000786	CcSEcCtD
Pemetrexed—Asthenia—Etoposide—urinary bladder cancer	1.96e-05	0.000784	CcSEcCtD
Pemetrexed—Urethral disorder—Doxorubicin—urinary bladder cancer	1.95e-05	0.000782	CcSEcCtD
Pemetrexed—Pruritus—Etoposide—urinary bladder cancer	1.93e-05	0.000773	CcSEcCtD
Pemetrexed—Arrhythmia—Epirubicin—urinary bladder cancer	1.92e-05	0.000771	CcSEcCtD
Pemetrexed—Alopecia—Epirubicin—urinary bladder cancer	1.9e-05	0.000762	CcSEcCtD
Pemetrexed—Nausea—Gemcitabine—urinary bladder cancer	1.9e-05	0.00076	CcSEcCtD
Pemetrexed—Vomiting—Cisplatin—urinary bladder cancer	1.89e-05	0.000759	CcSEcCtD
Pemetrexed—Erythema multiforme—Doxorubicin—urinary bladder cancer	1.88e-05	0.000755	CcSEcCtD
Pemetrexed—Rash—Cisplatin—urinary bladder cancer	1.88e-05	0.000752	CcSEcCtD
Pemetrexed—Dermatitis—Cisplatin—urinary bladder cancer	1.88e-05	0.000752	CcSEcCtD
Pemetrexed—Erythema—Epirubicin—urinary bladder cancer	1.87e-05	0.000751	CcSEcCtD
Pemetrexed—Malnutrition—Epirubicin—urinary bladder cancer	1.87e-05	0.000751	CcSEcCtD
Pemetrexed—Diarrhoea—Etoposide—urinary bladder cancer	1.87e-05	0.000748	CcSEcCtD
Pemetrexed—Nausea—Fluorouracil—urinary bladder cancer	1.87e-05	0.000748	CcSEcCtD
Pemetrexed—Eye disorder—Doxorubicin—urinary bladder cancer	1.86e-05	0.000746	CcSEcCtD
Pemetrexed—TYMS—E2F transcription factor network—MYC—urinary bladder cancer	1.85e-05	0.000711	CbGpPWpGaD
Pemetrexed—Anaemia—Methotrexate—urinary bladder cancer	1.85e-05	0.000742	CcSEcCtD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	1.85e-05	0.000708	CbGpPWpGaD
Pemetrexed—Dysgeusia—Epirubicin—urinary bladder cancer	1.83e-05	0.000735	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—RRM2—urinary bladder cancer	1.82e-05	0.000699	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—FAS—urinary bladder cancer	1.81e-05	0.000694	CbGpPWpGaD
Pemetrexed—Dizziness—Etoposide—urinary bladder cancer	1.8e-05	0.000723	CcSEcCtD
Pemetrexed—Leukopenia—Methotrexate—urinary bladder cancer	1.79e-05	0.000718	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	1.78e-05	0.000682	CbGpPWpGaD
Pemetrexed—Arrhythmia—Doxorubicin—urinary bladder cancer	1.78e-05	0.000713	CcSEcCtD
Pemetrexed—Nausea—Cisplatin—urinary bladder cancer	1.77e-05	0.000709	CcSEcCtD
Pemetrexed—Alopecia—Doxorubicin—urinary bladder cancer	1.76e-05	0.000705	CcSEcCtD
Pemetrexed—DHFR—Metabolism—GSTZ1—urinary bladder cancer	1.75e-05	0.00067	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—HPGDS—urinary bladder cancer	1.74e-05	0.000666	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—ENO2—urinary bladder cancer	1.74e-05	0.000666	CbGpPWpGaD
Pemetrexed—Vomiting—Etoposide—urinary bladder cancer	1.73e-05	0.000695	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	1.73e-05	0.000665	CbGpPWpGaD
Pemetrexed—Malnutrition—Doxorubicin—urinary bladder cancer	1.73e-05	0.000695	CcSEcCtD
Pemetrexed—Erythema—Doxorubicin—urinary bladder cancer	1.73e-05	0.000695	CcSEcCtD
Pemetrexed—Anaemia—Epirubicin—urinary bladder cancer	1.73e-05	0.000694	CcSEcCtD
Pemetrexed—Rash—Etoposide—urinary bladder cancer	1.72e-05	0.000689	CcSEcCtD
Pemetrexed—Dermatitis—Etoposide—urinary bladder cancer	1.72e-05	0.000689	CcSEcCtD
Pemetrexed—Chest pain—Methotrexate—urinary bladder cancer	1.7e-05	0.000683	CcSEcCtD
Pemetrexed—Myalgia—Methotrexate—urinary bladder cancer	1.7e-05	0.000683	CcSEcCtD
Pemetrexed—Arthralgia—Methotrexate—urinary bladder cancer	1.7e-05	0.000683	CcSEcCtD
Pemetrexed—Dysgeusia—Doxorubicin—urinary bladder cancer	1.7e-05	0.00068	CcSEcCtD
Pemetrexed—DCK—Metabolism—CYP4B1—urinary bladder cancer	1.7e-05	0.000651	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—NAT2—urinary bladder cancer	1.69e-05	0.000649	CbGpPWpGaD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	1.69e-05	0.000678	CcSEcCtD
Pemetrexed—ATIC—Metabolism—GSTT1—urinary bladder cancer	1.68e-05	0.000646	CbGpPWpGaD
Pemetrexed—GART—Metabolism—GSTP1—urinary bladder cancer	1.68e-05	0.000646	CbGpPWpGaD
Pemetrexed—Syncope—Epirubicin—urinary bladder cancer	1.68e-05	0.000673	CcSEcCtD
Pemetrexed—Leukopenia—Epirubicin—urinary bladder cancer	1.68e-05	0.000672	CcSEcCtD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	1.67e-05	0.000642	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	1.67e-05	0.000639	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	1.66e-05	0.000636	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTO2—urinary bladder cancer	1.66e-05	0.000635	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—NAT1—urinary bladder cancer	1.66e-05	0.000635	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	1.65e-05	0.000633	CbGpPWpGaD
Pemetrexed—Loss of consciousness—Epirubicin—urinary bladder cancer	1.65e-05	0.00066	CcSEcCtD
Pemetrexed—Anaphylactic shock—Methotrexate—urinary bladder cancer	1.63e-05	0.000655	CcSEcCtD
Pemetrexed—TYMS—G1/S Transition—CDKN1A—urinary bladder cancer	1.62e-05	0.000622	CbGpPWpGaD
Pemetrexed—Infection—Methotrexate—urinary bladder cancer	1.62e-05	0.000651	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	1.62e-05	0.000621	CbGpPWpGaD
Pemetrexed—Nausea—Etoposide—urinary bladder cancer	1.62e-05	0.000649	CcSEcCtD
Pemetrexed—Hypertension—Epirubicin—urinary bladder cancer	1.62e-05	0.000648	CcSEcCtD
Pemetrexed—SLC46A1—Disease—ENO2—urinary bladder cancer	1.62e-05	0.00062	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	1.61e-05	0.000618	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—SLC19A1—urinary bladder cancer	1.6e-05	0.000615	CbGpPWpGaD
Pemetrexed—Nervous system disorder—Methotrexate—urinary bladder cancer	1.6e-05	0.000642	CcSEcCtD
Pemetrexed—Anaemia—Doxorubicin—urinary bladder cancer	1.6e-05	0.000642	CcSEcCtD
Pemetrexed—Thrombocytopenia—Methotrexate—urinary bladder cancer	1.6e-05	0.000641	CcSEcCtD
Pemetrexed—Arthralgia—Epirubicin—urinary bladder cancer	1.59e-05	0.000639	CcSEcCtD
Pemetrexed—Chest pain—Epirubicin—urinary bladder cancer	1.59e-05	0.000639	CcSEcCtD
Pemetrexed—Myalgia—Epirubicin—urinary bladder cancer	1.59e-05	0.000639	CcSEcCtD
Pemetrexed—TYMS—Circadian rythm related genes—CDK4—urinary bladder cancer	1.59e-05	0.000611	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—RRM2—urinary bladder cancer	1.59e-05	0.00061	CbGpPWpGaD
Pemetrexed—Skin disorder—Methotrexate—urinary bladder cancer	1.59e-05	0.000636	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	1.58e-05	0.000635	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	1.57e-05	0.000601	CbGpPWpGaD
Pemetrexed—GART—Metabolism—TYMS—urinary bladder cancer	1.57e-05	0.0006	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PRSS3—urinary bladder cancer	1.56e-05	0.000599	CbGpPWpGaD
Pemetrexed—Anorexia—Methotrexate—urinary bladder cancer	1.56e-05	0.000624	CcSEcCtD
Pemetrexed—Syncope—Doxorubicin—urinary bladder cancer	1.55e-05	0.000623	CcSEcCtD
Pemetrexed—Leukopenia—Doxorubicin—urinary bladder cancer	1.55e-05	0.000622	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—SMC1A—urinary bladder cancer	1.55e-05	0.000595	CbGpPWpGaD
Pemetrexed—GART—Metabolism—GSTM1—urinary bladder cancer	1.55e-05	0.000594	CbGpPWpGaD
Pemetrexed—GART—Metabolism—NCOR1—urinary bladder cancer	1.55e-05	0.000594	CbGpPWpGaD
Pemetrexed—DHFR—G1/S Transition—MYC—urinary bladder cancer	1.54e-05	0.000591	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SLC19A1—urinary bladder cancer	1.54e-05	0.00059	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—RBX1—urinary bladder cancer	1.53e-05	0.000587	CbGpPWpGaD
Pemetrexed—Oedema—Epirubicin—urinary bladder cancer	1.53e-05	0.000613	CcSEcCtD
Pemetrexed—Anaphylactic shock—Epirubicin—urinary bladder cancer	1.53e-05	0.000613	CcSEcCtD
Pemetrexed—TYMS—Metabolism—GSTZ1—urinary bladder cancer	1.52e-05	0.000585	CbGpPWpGaD
Pemetrexed—Loss of consciousness—Doxorubicin—urinary bladder cancer	1.52e-05	0.000611	CcSEcCtD
Pemetrexed—Infection—Epirubicin—urinary bladder cancer	1.52e-05	0.000609	CcSEcCtD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	1.52e-05	0.000582	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—UGT2B7—urinary bladder cancer	1.51e-05	0.000581	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	1.51e-05	0.00058	CbGpPWpGaD
Pemetrexed—Shock—Epirubicin—urinary bladder cancer	1.5e-05	0.000603	CcSEcCtD
Pemetrexed—Nervous system disorder—Epirubicin—urinary bladder cancer	1.5e-05	0.000601	CcSEcCtD
Pemetrexed—DHFR—Disease—PRSS3—urinary bladder cancer	1.5e-05	0.000575	CbGpPWpGaD
Pemetrexed—Thrombocytopenia—Epirubicin—urinary bladder cancer	1.5e-05	0.0006	CcSEcCtD
Pemetrexed—Hypertension—Doxorubicin—urinary bladder cancer	1.5e-05	0.0006	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	1.49e-05	0.000597	CcSEcCtD
Pemetrexed—Skin disorder—Epirubicin—urinary bladder cancer	1.49e-05	0.000595	CcSEcCtD
Pemetrexed—GART—Metabolism—GPX1—urinary bladder cancer	1.48e-05	0.000568	CbGpPWpGaD
Pemetrexed—Myalgia—Doxorubicin—urinary bladder cancer	1.48e-05	0.000591	CcSEcCtD
Pemetrexed—Chest pain—Doxorubicin—urinary bladder cancer	1.48e-05	0.000591	CcSEcCtD
Pemetrexed—Arthralgia—Doxorubicin—urinary bladder cancer	1.48e-05	0.000591	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	1.47e-05	0.000587	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—RRM2—urinary bladder cancer	1.46e-05	0.00056	CbGpPWpGaD
Pemetrexed—Anorexia—Epirubicin—urinary bladder cancer	1.46e-05	0.000584	CcSEcCtD
Pemetrexed—Dyspnoea—Methotrexate—urinary bladder cancer	1.46e-05	0.000584	CcSEcCtD
Pemetrexed—GART—Metabolism—ERCC2—urinary bladder cancer	1.46e-05	0.000558	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	1.45e-05	0.000555	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—PPARG—urinary bladder cancer	1.45e-05	0.000555	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NAT1—urinary bladder cancer	1.45e-05	0.000554	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTO2—urinary bladder cancer	1.45e-05	0.000554	CbGpPWpGaD
Pemetrexed—Dyspepsia—Methotrexate—urinary bladder cancer	1.44e-05	0.000576	CcSEcCtD
Pemetrexed—DHFR—Disease—HDAC4—urinary bladder cancer	1.43e-05	0.000548	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	1.43e-05	0.000548	CbGpPWpGaD
Pemetrexed—Decreased appetite—Methotrexate—urinary bladder cancer	1.42e-05	0.000569	CcSEcCtD
Pemetrexed—Anaphylactic shock—Doxorubicin—urinary bladder cancer	1.41e-05	0.000567	CcSEcCtD
Pemetrexed—Oedema—Doxorubicin—urinary bladder cancer	1.41e-05	0.000567	CcSEcCtD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	1.41e-05	0.000542	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	1.41e-05	0.000565	CcSEcCtD
Pemetrexed—Fatigue—Methotrexate—urinary bladder cancer	1.41e-05	0.000565	CcSEcCtD
Pemetrexed—Infection—Doxorubicin—urinary bladder cancer	1.41e-05	0.000563	CcSEcCtD
Pemetrexed—ATIC—Metabolism—NQO1—urinary bladder cancer	1.4e-05	0.000537	CbGpPWpGaD
Pemetrexed—Pain—Methotrexate—urinary bladder cancer	1.4e-05	0.00056	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	1.39e-05	0.000558	CcSEcCtD
Pemetrexed—Shock—Doxorubicin—urinary bladder cancer	1.39e-05	0.000558	CcSEcCtD
Pemetrexed—Nervous system disorder—Doxorubicin—urinary bladder cancer	1.39e-05	0.000556	CcSEcCtD
Pemetrexed—Thrombocytopenia—Doxorubicin—urinary bladder cancer	1.39e-05	0.000555	CcSEcCtD
Pemetrexed—Skin disorder—Doxorubicin—urinary bladder cancer	1.37e-05	0.000551	CcSEcCtD
Pemetrexed—SLC46A1—Disease—JAG1—urinary bladder cancer	1.37e-05	0.000526	CbGpPWpGaD
Pemetrexed—GART—Metabolism—MTHFR—urinary bladder cancer	1.37e-05	0.000525	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	1.37e-05	0.000525	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP4B1—urinary bladder cancer	1.36e-05	0.000523	CbGpPWpGaD
Pemetrexed—Dyspnoea—Epirubicin—urinary bladder cancer	1.36e-05	0.000546	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—HPGDS—urinary bladder cancer	1.35e-05	0.000519	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—ENO2—urinary bladder cancer	1.35e-05	0.000519	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—SMC1A—urinary bladder cancer	1.35e-05	0.000519	CbGpPWpGaD
Pemetrexed—Anorexia—Doxorubicin—urinary bladder cancer	1.35e-05	0.00054	CcSEcCtD
Pemetrexed—TYMS—G1/S Transition—MYC—urinary bladder cancer	1.35e-05	0.000516	CbGpPWpGaD
Pemetrexed—Dyspepsia—Epirubicin—urinary bladder cancer	1.35e-05	0.000539	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Methotrexate—urinary bladder cancer	1.34e-05	0.000535	CcSEcCtD
Pemetrexed—Decreased appetite—Epirubicin—urinary bladder cancer	1.33e-05	0.000533	CcSEcCtD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	1.32e-05	0.000508	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—UGT2B7—urinary bladder cancer	1.32e-05	0.000507	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	1.32e-05	0.000529	CcSEcCtD
Pemetrexed—Fatigue—Epirubicin—urinary bladder cancer	1.32e-05	0.000528	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—GSTT1—urinary bladder cancer	1.31e-05	0.000503	CbGpPWpGaD
Pemetrexed—Pain—Epirubicin—urinary bladder cancer	1.31e-05	0.000524	CcSEcCtD
Pemetrexed—Constipation—Epirubicin—urinary bladder cancer	1.31e-05	0.000524	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	1.3e-05	0.000498	CbGpPWpGaD
Pemetrexed—Urticaria—Methotrexate—urinary bladder cancer	1.3e-05	0.00052	CcSEcCtD
Pemetrexed—Body temperature increased—Methotrexate—urinary bladder cancer	1.29e-05	0.000518	CcSEcCtD
Pemetrexed—Abdominal pain—Methotrexate—urinary bladder cancer	1.29e-05	0.000518	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	1.29e-05	0.000517	CcSEcCtD
Pemetrexed—DHFR—Metabolism—SLC19A1—urinary bladder cancer	1.29e-05	0.000494	CbGpPWpGaD
Pemetrexed—Dyspnoea—Doxorubicin—urinary bladder cancer	1.26e-05	0.000505	CcSEcCtD
Pemetrexed—DHFR—Metabolism—PRSS3—urinary bladder cancer	1.26e-05	0.000481	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Epirubicin—urinary bladder cancer	1.25e-05	0.000501	CcSEcCtD
Pemetrexed—DCK—Metabolism—TYMP—urinary bladder cancer	1.25e-05	0.000479	CbGpPWpGaD
Pemetrexed—Dyspepsia—Doxorubicin—urinary bladder cancer	1.25e-05	0.000499	CcSEcCtD
Pemetrexed—Decreased appetite—Doxorubicin—urinary bladder cancer	1.23e-05	0.000493	CcSEcCtD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.23e-05	0.000471	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	1.22e-05	0.00049	CcSEcCtD
Pemetrexed—Fatigue—Doxorubicin—urinary bladder cancer	1.22e-05	0.000489	CcSEcCtD
Pemetrexed—Urticaria—Epirubicin—urinary bladder cancer	1.21e-05	0.000487	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.21e-05	0.000465	CbGpPWpGaD
Pemetrexed—Constipation—Doxorubicin—urinary bladder cancer	1.21e-05	0.000485	CcSEcCtD
Pemetrexed—Pain—Doxorubicin—urinary bladder cancer	1.21e-05	0.000485	CcSEcCtD
Pemetrexed—Body temperature increased—Epirubicin—urinary bladder cancer	1.21e-05	0.000484	CcSEcCtD
Pemetrexed—Abdominal pain—Epirubicin—urinary bladder cancer	1.21e-05	0.000484	CcSEcCtD
Pemetrexed—Hypersensitivity—Methotrexate—urinary bladder cancer	1.2e-05	0.000482	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	1.2e-05	0.000461	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP4B1—urinary bladder cancer	1.19e-05	0.000456	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.19e-05	0.000455	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	1.18e-05	0.000453	CbGpPWpGaD
Pemetrexed—Asthenia—Methotrexate—urinary bladder cancer	1.17e-05	0.00047	CcSEcCtD
Pemetrexed—ATIC—Metabolism—GSTP1—urinary bladder cancer	1.17e-05	0.000448	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	1.16e-05	0.000464	CcSEcCtD
Pemetrexed—Pruritus—Methotrexate—urinary bladder cancer	1.16e-05	0.000463	CcSEcCtD
Pemetrexed—DHFR—Disease—LIG1—urinary bladder cancer	1.14e-05	0.000436	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	1.13e-05	0.000435	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—NAT2—urinary bladder cancer	1.13e-05	0.000433	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Epirubicin—urinary bladder cancer	1.13e-05	0.000451	CcSEcCtD
Pemetrexed—TYMS—Metabolism—SLC19A1—urinary bladder cancer	1.12e-05	0.000431	CbGpPWpGaD
Pemetrexed—Urticaria—Doxorubicin—urinary bladder cancer	1.12e-05	0.00045	CcSEcCtD
Pemetrexed—Body temperature increased—Doxorubicin—urinary bladder cancer	1.12e-05	0.000448	CcSEcCtD
Pemetrexed—Abdominal pain—Doxorubicin—urinary bladder cancer	1.12e-05	0.000448	CcSEcCtD
Pemetrexed—Diarrhoea—Methotrexate—urinary bladder cancer	1.12e-05	0.000448	CcSEcCtD
Pemetrexed—GART—Metabolism—PPARG—urinary bladder cancer	1.11e-05	0.000425	CbGpPWpGaD
Pemetrexed—Asthenia—Epirubicin—urinary bladder cancer	1.1e-05	0.00044	CcSEcCtD
Pemetrexed—TYMS—Metabolism—PRSS3—urinary bladder cancer	1.1e-05	0.00042	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—NQO1—urinary bladder cancer	1.09e-05	0.000418	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—TYMS—urinary bladder cancer	1.09e-05	0.000416	CbGpPWpGaD
Pemetrexed—Pruritus—Epirubicin—urinary bladder cancer	1.08e-05	0.000434	CcSEcCtD
Pemetrexed—Dizziness—Methotrexate—urinary bladder cancer	1.08e-05	0.000433	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—CCNE1—urinary bladder cancer	1.07e-05	0.000412	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—NCOR1—urinary bladder cancer	1.07e-05	0.000411	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—GSTM1—urinary bladder cancer	1.07e-05	0.000411	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.07e-05	0.000411	CbGpPWpGaD
Pemetrexed—GART—Metabolism—CREBBP—urinary bladder cancer	1.07e-05	0.000409	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TYMS—urinary bladder cancer	1.06e-05	0.000405	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	1.05e-05	0.000402	CbGpPWpGaD
Pemetrexed—Diarrhoea—Epirubicin—urinary bladder cancer	1.05e-05	0.000419	CcSEcCtD
Pemetrexed—Hypersensitivity—Doxorubicin—urinary bladder cancer	1.04e-05	0.000418	CcSEcCtD
Pemetrexed—Vomiting—Methotrexate—urinary bladder cancer	1.04e-05	0.000416	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.04e-05	0.000397	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.03e-05	0.000396	CbGpPWpGaD
Pemetrexed—Rash—Methotrexate—urinary bladder cancer	1.03e-05	0.000413	CcSEcCtD
Pemetrexed—Dermatitis—Methotrexate—urinary bladder cancer	1.03e-05	0.000412	CcSEcCtD
Pemetrexed—ATIC—Metabolism—GPX1—urinary bladder cancer	1.03e-05	0.000394	CbGpPWpGaD
Pemetrexed—Asthenia—Doxorubicin—urinary bladder cancer	1.02e-05	0.000407	CcSEcCtD
Pemetrexed—Dizziness—Epirubicin—urinary bladder cancer	1.01e-05	0.000405	CcSEcCtD
Pemetrexed—ATIC—Metabolism—ERCC2—urinary bladder cancer	1.01e-05	0.000387	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—TYMP—urinary bladder cancer	1e-05	0.000385	CbGpPWpGaD
Pemetrexed—Pruritus—Doxorubicin—urinary bladder cancer	1e-05	0.000401	CcSEcCtD
Pemetrexed—SLC46A1—Disease—NCOR1—urinary bladder cancer	9.98e-06	0.000383	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—PTEN—urinary bladder cancer	9.93e-06	0.000381	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	9.86e-06	0.000378	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—RRM2—urinary bladder cancer	9.75e-06	0.000374	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	9.74e-06	0.000374	CbGpPWpGaD
Pemetrexed—Vomiting—Epirubicin—urinary bladder cancer	9.72e-06	0.00039	CcSEcCtD
Pemetrexed—Nausea—Methotrexate—urinary bladder cancer	9.7e-06	0.000389	CcSEcCtD
Pemetrexed—Diarrhoea—Doxorubicin—urinary bladder cancer	9.68e-06	0.000388	CcSEcCtD
Pemetrexed—Rash—Epirubicin—urinary bladder cancer	9.64e-06	0.000386	CcSEcCtD
Pemetrexed—Dermatitis—Epirubicin—urinary bladder cancer	9.63e-06	0.000386	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	9.59e-06	0.000368	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—MTHFR—urinary bladder cancer	9.48e-06	0.000364	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—EP300—urinary bladder cancer	9.47e-06	0.000363	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—ERCC2—urinary bladder cancer	9.39e-06	0.00036	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCNE1—urinary bladder cancer	9.38e-06	0.00036	CbGpPWpGaD
Pemetrexed—Dizziness—Doxorubicin—urinary bladder cancer	9.36e-06	0.000375	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	9.2e-06	0.000353	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TERT—urinary bladder cancer	9.2e-06	0.000353	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GSTP1—urinary bladder cancer	9.1e-06	0.000349	CbGpPWpGaD
Pemetrexed—Nausea—Epirubicin—urinary bladder cancer	9.08e-06	0.000364	CcSEcCtD
Pemetrexed—DHFR—Metabolism—NAT2—urinary bladder cancer	9.08e-06	0.000348	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ENO2—urinary bladder cancer	9.03e-06	0.000346	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—HPGDS—urinary bladder cancer	9.03e-06	0.000346	CbGpPWpGaD
Pemetrexed—Vomiting—Doxorubicin—urinary bladder cancer	9e-06	0.000361	CcSEcCtD
Pemetrexed—Rash—Doxorubicin—urinary bladder cancer	8.92e-06	0.000357	CcSEcCtD
Pemetrexed—Dermatitis—Doxorubicin—urinary bladder cancer	8.91e-06	0.000357	CcSEcCtD
Pemetrexed—SLC46A1—Disease—MTHFR—urinary bladder cancer	8.82e-06	0.000338	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TERT—urinary bladder cancer	8.8e-06	0.000337	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—TYMP—urinary bladder cancer	8.76e-06	0.000336	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTT1—urinary bladder cancer	8.76e-06	0.000336	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PTGS2—urinary bladder cancer	8.73e-06	0.000335	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ENO2—urinary bladder cancer	8.66e-06	0.000332	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	8.59e-06	0.000329	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—TYMS—urinary bladder cancer	8.46e-06	0.000324	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	8.41e-06	0.000322	CbGpPWpGaD
Pemetrexed—Nausea—Doxorubicin—urinary bladder cancer	8.4e-06	0.000337	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—GSTM1—urinary bladder cancer	8.36e-06	0.000321	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—NCOR1—urinary bladder cancer	8.36e-06	0.000321	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—ATM—urinary bladder cancer	8.26e-06	0.000317	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDK4—urinary bladder cancer	8.23e-06	0.000316	CbGpPWpGaD
Pemetrexed—DHFR—Disease—RBX1—urinary bladder cancer	8.21e-06	0.000315	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—FGFR3—urinary bladder cancer	8.07e-06	0.00031	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	8.03e-06	0.000308	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TERT—urinary bladder cancer	8.02e-06	0.000308	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GPX1—urinary bladder cancer	8.01e-06	0.000307	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	8e-06	0.000307	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—RB1—urinary bladder cancer	8e-06	0.000307	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	7.94e-06	0.000304	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NAT2—urinary bladder cancer	7.92e-06	0.000304	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—ERCC2—urinary bladder cancer	7.86e-06	0.000301	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—RRM2—urinary bladder cancer	7.83e-06	0.0003	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PPARG—urinary bladder cancer	7.69e-06	0.000295	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PTEN—urinary bladder cancer	7.61e-06	0.000292	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—MTHFR—urinary bladder cancer	7.39e-06	0.000283	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—CREBBP—urinary bladder cancer	7.39e-06	0.000283	CbGpPWpGaD
Pemetrexed—DHFR—Disease—JAG1—urinary bladder cancer	7.35e-06	0.000282	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—NQO1—urinary bladder cancer	7.28e-06	0.000279	CbGpPWpGaD
Pemetrexed—GART—Metabolism—EP300—urinary bladder cancer	7.26e-06	0.000278	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—HPGDS—urinary bladder cancer	7.26e-06	0.000278	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ENO2—urinary bladder cancer	7.26e-06	0.000278	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—ATM—urinary bladder cancer	7.21e-06	0.000277	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDK4—urinary bladder cancer	7.18e-06	0.000275	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—RB1—urinary bladder cancer	7.16e-06	0.000274	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	7.06e-06	0.000271	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTT1—urinary bladder cancer	7.04e-06	0.00027	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	7.04e-06	0.00027	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—RB1—urinary bladder cancer	6.98e-06	0.000268	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CREBBP—urinary bladder cancer	6.87e-06	0.000263	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—RRM2—urinary bladder cancer	6.84e-06	0.000262	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—TP53—urinary bladder cancer	6.77e-06	0.00026	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ENO2—urinary bladder cancer	6.33e-06	0.000243	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—HPGDS—urinary bladder cancer	6.33e-06	0.000243	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN2A—urinary bladder cancer	6.29e-06	0.000241	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—RB1—urinary bladder cancer	6.24e-06	0.000239	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—RHOA—urinary bladder cancer	6.22e-06	0.000238	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTT1—urinary bladder cancer	6.14e-06	0.000235	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	6.14e-06	0.000235	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTP1—urinary bladder cancer	6.07e-06	0.000233	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTGS2—urinary bladder cancer	6.05e-06	0.000232	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PPARG—urinary bladder cancer	5.99e-06	0.00023	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	5.94e-06	0.000228	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—NQO1—urinary bladder cancer	5.85e-06	0.000224	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CREBBP—urinary bladder cancer	5.76e-06	0.000221	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—ERBB2—urinary bladder cancer	5.76e-06	0.000221	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	5.75e-06	0.00022	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—TYMS—urinary bladder cancer	5.64e-06	0.000216	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTGS2—urinary bladder cancer	5.63e-06	0.000216	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—NCOR1—urinary bladder cancer	5.58e-06	0.000214	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTM1—urinary bladder cancer	5.58e-06	0.000214	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN2A—urinary bladder cancer	5.49e-06	0.00021	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—EP300—urinary bladder cancer	5.47e-06	0.00021	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NCOR1—urinary bladder cancer	5.35e-06	0.000205	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GPX1—urinary bladder cancer	5.34e-06	0.000205	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CCND1—urinary bladder cancer	5.31e-06	0.000204	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTEN—urinary bladder cancer	5.28e-06	0.000202	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ERCC2—urinary bladder cancer	5.24e-06	0.000201	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	5.19e-06	0.000199	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN1A—urinary bladder cancer	5.14e-06	0.000197	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NQO1—urinary bladder cancer	5.1e-06	0.000196	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ERCC2—urinary bladder cancer	5.03e-06	0.000193	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—EP300—urinary bladder cancer	5.03e-06	0.000193	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	5.02e-06	0.000192	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—MTHFR—urinary bladder cancer	4.93e-06	0.000189	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN1A—urinary bladder cancer	4.92e-06	0.000189	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTEN—urinary bladder cancer	4.91e-06	0.000188	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—EP300—urinary bladder cancer	4.89e-06	0.000188	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTP1—urinary bladder cancer	4.88e-06	0.000187	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—EP300—urinary bladder cancer	4.77e-06	0.000183	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MYC—urinary bladder cancer	4.77e-06	0.000183	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MTHFR—urinary bladder cancer	4.73e-06	0.000181	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TERT—urinary bladder cancer	4.72e-06	0.000181	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTGS2—urinary bladder cancer	4.71e-06	0.000181	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EP300—urinary bladder cancer	4.68e-06	0.000179	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCND1—urinary bladder cancer	4.64e-06	0.000178	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—SRC—urinary bladder cancer	4.55e-06	0.000175	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—TYMS—urinary bladder cancer	4.53e-06	0.000174	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN1A—urinary bladder cancer	4.49e-06	0.000172	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTM1—urinary bladder cancer	4.48e-06	0.000172	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—NCOR1—urinary bladder cancer	4.48e-06	0.000172	CbGpPWpGaD
Pemetrexed—DHFR—Disease—FGFR3—urinary bladder cancer	4.33e-06	0.000166	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GPX1—urinary bladder cancer	4.29e-06	0.000165	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—EP300—urinary bladder cancer	4.27e-06	0.000164	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MYC—urinary bladder cancer	4.26e-06	0.000163	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTP1—urinary bladder cancer	4.26e-06	0.000163	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ERCC2—urinary bladder cancer	4.21e-06	0.000162	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MYC—urinary bladder cancer	4.16e-06	0.00016	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTEN—urinary bladder cancer	4.11e-06	0.000158	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MYC—urinary bladder cancer	4.08e-06	0.000156	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PPARG—urinary bladder cancer	4e-06	0.000153	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EGFR—urinary bladder cancer	3.99e-06	0.000153	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—MTHFR—urinary bladder cancer	3.96e-06	0.000152	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—EP300—urinary bladder cancer	3.92e-06	0.00015	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTM1—urinary bladder cancer	3.91e-06	0.00015	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NCOR1—urinary bladder cancer	3.91e-06	0.00015	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CREBBP—urinary bladder cancer	3.84e-06	0.000147	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—KRAS—urinary bladder cancer	3.77e-06	0.000144	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GPX1—urinary bladder cancer	3.75e-06	0.000144	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MYC—urinary bladder cancer	3.72e-06	0.000143	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CREBBP—urinary bladder cancer	3.68e-06	0.000141	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ERCC2—urinary bladder cancer	3.68e-06	0.000141	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TP53—urinary bladder cancer	3.5e-06	0.000134	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—MTHFR—urinary bladder cancer	3.46e-06	0.000133	CbGpPWpGaD
Pemetrexed—DHFR—Disease—RHOA—urinary bladder cancer	3.33e-06	0.000128	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PPARG—urinary bladder cancer	3.21e-06	0.000123	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—HRAS—urinary bladder cancer	3.2e-06	0.000123	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTGS2—urinary bladder cancer	3.14e-06	0.000121	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CREBBP—urinary bladder cancer	3.09e-06	0.000118	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ERBB2—urinary bladder cancer	3.09e-06	0.000118	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TP53—urinary bladder cancer	3.05e-06	0.000117	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTGS2—urinary bladder cancer	3.02e-06	0.000116	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PPARG—urinary bladder cancer	2.8e-06	0.000107	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTEN—urinary bladder cancer	2.74e-06	0.000105	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CREBBP—urinary bladder cancer	2.69e-06	0.000103	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDKN1A—urinary bladder cancer	2.64e-06	0.000101	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTEN—urinary bladder cancer	2.63e-06	0.000101	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—EP300—urinary bladder cancer	2.62e-06	0.0001	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTGS2—urinary bladder cancer	2.53e-06	9.69e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EP300—urinary bladder cancer	2.51e-06	9.62e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SRC—urinary bladder cancer	2.44e-06	9.36e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTGS2—urinary bladder cancer	2.21e-06	8.45e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTEN—urinary bladder cancer	2.2e-06	8.45e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MYC—urinary bladder cancer	2.19e-06	8.38e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EGFR—urinary bladder cancer	2.14e-06	8.2e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—EP300—urinary bladder cancer	2.1e-06	8.06e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KRAS—urinary bladder cancer	2.02e-06	7.75e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTEN—urinary bladder cancer	1.92e-06	7.37e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—EP300—urinary bladder cancer	1.83e-06	7.03e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HRAS—urinary bladder cancer	1.72e-06	6.59e-05	CbGpPWpGaD
